Contact

Independent information resource Safety first · Evidence clarity Ventriva An independent resource on ibogaine’s cardiac safety risks. Home About Services Cardiac Risks Risk Modifiers How Risk Is Assessed Contact Cardiac safety briefing · August 2026 Cardiac Risk of Ibogaine Use Ibogaine’s potential in addiction treatment cannot be separated from a central safety fact: its effects on the heart’s electrical rhythm can be serious, prolonged, and sometimes fatal. Cardiac risk is the central safety question in ibogaine treatment. Image: Ventriva Ventriva · Independent resource For people evaluating ibogaine, families, researchers & policymakers Ibogaine is an indole alkaloid derived from the Tabernanthe iboga plant, known for anti-addictive and psychotropic effects. Interest in ibogaine treatment often centers on drug dependence, opioid withdrawal, and substance use disorder. But cardiac risk of ibogaine use requires equal attention because the cardiovascular system can be affected during and after dosing. Iboga alkaloids influence opioid, serotonin, and dopamine receptors, as well as the central nervous system. Those multiple actions may help explain why people seek ibogaine treatment for addiction treatment and detoxification, but they also make a simple safety prediction difficult. A useful starting point is the overview of ibogaine , which describes its origin and complex pharmacology. The primary metabolite, noribogaine, has a longer half-life—up to about 30 hours—than ibogaine itself. Noribogaine may contribute to both therapeutic effects and prolonged cardiac risk. That means the visible psychoactive period does not define the whole period of concern for cardiac arrhythmias, heart rate changes, or cardiac monitoring. For people considering treatment abroad, discussions of ibogaine care in Mexico should not substitute for an individualized risk assessment. Medical history, drug interactions, electrolyte imbalances, and pre-existing cardiac conditions can change

Contact

A note on reaching us